STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 601–700 of 1,004
Semaan, A., Bernard, V., Lee, J. J., Wong, J., Huang, J. H., Swartzlander, D. B., Stephens, B. M., Monberg, M. E., Weston, B. R., Bhutani, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2667 · Cited by 26
“STK11 loss, for example, has been repeatedly linked to the development of immunotherapy resistance inKRASmutant lung cancer (40), and PD-L1 loss is associated with adaptive immune resistance in Hodgkin lymphoma and other neoplastic diseases (41).”
BackgroundSelf-citationWhole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
Carrot‐Zhang, J., Yao, X., Devarakonda, S. H. K., Deshpande, A. S., Damrauer, J. S., Silva, T. C., Wong, C. K., Choi, H. Y., Felau, I., Robertson, A. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108784 · Cited by 37
Self-citationResistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 27
Liu, Y., Li, H., Zhu, J., Zhang, Y., Liu, X., Li, R., Zhang, Q., & Cheng, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s282617 · Cited by 23
“Conversely, tumors harboring concurrent KRAS and STK11 mutations could be associated with an immunosuppressive microenvironment.(26,27) Furthermore, the absence of PTEN promotes resistance to T cellmediated immunotherapy.”
BackgroundClinical and technical insights of tumour mutational burden in non-small cell lung cancer
Meri-Abad, M., Moreno‐Manuel, A., Gallach, S., Fariñas, S. C., Sirera, R., Herrero, C. C., & Lewintre, E. J. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103891 · Cited by 29
Proulx-Rocray, F., Routy, B., Nassabein, R. M., Belkaïd, W., Tran‐Thanh, D., Malo, J., Tonneau, M., Ouarzadi, O. E., Florescu, M., Tehfe, M. A., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100767 · Cited by 39
Adam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 28
“STING transcriptional silencing via mutational STK11/LKB1 inactivation led to insensitivity to cytoplasmic double stranded deoxyribonucleic acid (dsDNA) detection and an inability to mount an appropriate immune response [50].”
BackgroundBorzi, C., Ganzinelli, M., Caiola, E., Colombo, M., Centonze, G., Boeri, M., Signorelli, D., Caleca, L., Rulli, E., Busico, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.005 · Cited by 24
Lung Cancer with a High Tumor Mutational Burden
VanderLaan, P. A., Rangachari, D., & Costa, D. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1808566 · Cited by 24
Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043618 · Cited by 23
“Previous studies have also suggested that some genetic alterations in the tumor cells, such as somatic mutations in serine/threonine kinase 11 (STK11) or in kelch-like ECH-associated protein 1 (KEAP1), could serve as biomarkers to predict responses to ICIs in NSCLC [20,21].”
Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
Dong, J., Li, B., Zhou, Q., & Huang, D. (2018) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12322 · Cited by 25
Salehi‐Rad, R., Li, R., Tran, L. M., Lim, R. J., Abascal, J. W., Momcilovic, M., Park, S. J., Ong, S. L., Shabihkhani, M., Huang, Z. L., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02837-9 · Cited by 25
“This result is in agreement with the recent findings in human KRAS-mutant lung adenocarcinoma in which LKB1 loss was shown to be a major driver of primary resistance to PD-1 blockade [20].”
Gregorc, V., Lazzari, C., Mandalà, M., Ippati, S., Bulotta, A., Cangi, M. G., Khater, A., Viganò, M. G., Mirabile, A., Pecciarini, L., et al. (2021) · Cancers · doi:10.3390/cancers13092023 · Cited by 26
“7%) and shorter progression free survival (PFS) and overall survival (OS) in those patients included in the KL subgroup compared with those in the KP subgroup [25].”
ResultExploration of Prognostic Biomarkers for Lung Adenocarcinoma Through Bioinformatics Analysis
Tu, Z., He, X., Zeng, L., Meng, D., Zhuang, R., Zhao, J., & Dai, W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.647521 · Cited by 26
“Drug treatment targets cancer cell metabolic characteristics or transcription and translation and cell structure characteristics, so as to treat LUAD through specific pathways targeting cancer cells (Saito et al., 2016; Scafoglio et al., 2018; Skoulidis et al., 2018).”
BackgroundXie, W., Lu, J., Guo, Z., Guo, X., Chi, Y., Ye, J., Zhang, J., Xu, W., Zhao, L., & Wei, Y. (2021) · Nano Research · doi:10.1007/s12274-021-3763-7 · Cited by 25
Self-citationYang, H., Ma, W., Sun, B., Fan, L., Xu, K., Hall, S. R. R., Al-Hurani, M. F., Schmid, R. A., Peng, R., Hida, T., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-734 · Cited by 25
“, KEAP1, STK11) (56,57) that relate to the response to ICIs.”
BackgroundTang, Y., Cui, Y., Li, L., Guan, Y., Feng, D., Yin, B., Liang, X.-F., Yin, J., Jiang, R., Liang, J., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s329963 · Cited by 25
Self-citationDowlati, A., Abbas, A., Chan, T. A.-T., Henick, B. S., Wang, X., Doshi, P. D., Fu, P., Patel, J. D., Kuo, F., Chang, H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00257 · Cited by 28
Self-citationCai, R., Zhu, H., Liu, Y. L., Sha, H., Peng, W., Yin, R. L., Zhou, G., & Fang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04919-4 · Cited by 31
Boeschen, M., Kuhn, C. K., Wirtz, H. R. W., Seyfarth, H., Frille, A., Lordick, F., Hacker, U. T., Obeck, U., Stiller, M., Bläker, H., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107361 · Cited by 33
Zhou, L., Yang, J., Zhang, K., Wang, T., Jiang, S., & Zhang, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01361 · Cited by 24
Zheng, J., Deng, Y., Huang, B., & Chen, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1387896 · Cited by 27
Immunotherapeutic Advances for NSCLC
Massafra, M., Passalacqua, M. I., Gebbia, V., Macrì, P., Lazzari, C., Gregorc, V., Buda, C. A., Altavilla, G., & Santarpía, M. (2021) · Biologics · doi:10.2147/btt.s295406 · Cited by 31
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernández-García, F., Fernández-Rodríguez, A., Torre, C. F., Piñeiro-Yáñez, E., Wang, H., Lechuga, C. G., Callejas, S., Álvarez, R., López-García, A., Esteban-Burgos, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402913121 · Cited by 23
“On the contrary, inactivating somatic mutations in LKB1 have emerged as a major genomic driver of primary resistance to immune checkpoint inhibitors in non–small cell lung cancer ( 49 ).”
Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients
Alborelli, I., Hench, I. B., Chijioke, O., Prince, S. S., Bubendorf, L., Leuenberger, L. P., Tolnay, M., Leonards, K., Quagliata, L., Jermann, P. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.019 · Cited by 26
New biomarkers for checkpoint inhibitor therapy
Burdett, N. L., & Desai, J. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000597 · Cited by 25
Jin, R., Liu, B., Liu, X., Fan, Y., Peng, W., Huang, C., Marcus, A. I., Sica, G., Gilbert‐Ross, M., Liu, Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0567 · Cited by 24
“Furthermore, several clinical trials have demonstrated that lung cancers with LKB1inactivation are not responsive to immune checkpoint blockade therapy (13, 14).”
BackgroundNedd9 Restrains Autophagy to Limit Growth of Early Stage Non–Small Cell Lung Cancer
Deneka, A. Y., Kopp, M. C., Nikonova, A. S., Gaponova, A. V., Kiseleva, A. A., Hensley, H. H., Flieder, D. B., Serebriiskii, I. G., & Golemis, E. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3626 · Cited by 26
Fan, T. T., Pan, S., Yang, S., Hao, B., Zhang, L., Li, D., & Geng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693062 · Cited by 27
“Patients with different EGFR, KRAS, TP53, and STK11 mutation status were closely related to their prognosis and immunotherapy response (24, 25).”
BackgroundJin, Y. J., Xue, Q., Shen, X., Zheng, Q., Chen, H., Zhou, X., & Li, Y. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.009 · Cited by 22
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance
Shi, Z., Tu, J., Ying, Y., Diao, Y., Zhang, P., Liao, S., Xiong, Z., & Huang, S. (2022) · Cancers · doi:10.3390/cancers14174251 · Cited by 21
“However, many factors can contribute to resistance to PD-1/PD-L1 inhibitors, such as the presence of STK11 and KEAP1 mutations [64].”
BackgroundDirect GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 24
Tumor loss-of-function mutations in STK11/LKB1 induce cachexia
Iyengar, P., Gandhi, A. Y., Granados, J. Z., Guo, T., Gupta, A. K. D., Yu, J., Llano, E. M., Zhang, F., Gao, A., Kandathil, A., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165419 · Cited by 30
“This altered innate immune response in patients with NSCLC STK11/LKB1 variants is associated with resistance to standard immuno-oncology (IO) agents that rely primarily on an adaptive immune response (11, 32).”
BackgroundImmune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
Hallqvist, A., Rohlin, A., & Raghavan, S. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12980 · Cited by 25
Huang, R. S. P., Severson, E. A., Haberberger, J., Duncan, D. L., Hemmerich, A. C., Edgerly, C. I., Ferguson, N. L., Frampton, G. M., Owens, C., Williams, E. A., et al. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.592997 · Cited by 22
“Adding to the complexity are potential resistance biomarkers such as STK11 , KEAP1 , and EGFR for checkpoint inhibitors (CPIs) [10 – 12].”
Self-citationBahce, I., Dickhoff, C., Schneiders, F. L., Veltman, J. D., Heineman, D. J., Hashemi, S. M. S., Vrijmoet, A., Houda, I., Ulas, E. B., Bakker, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009799 · Cited by 30
Gandhi, M. M., Elkrief, A., Moore, C. G., Ricciuti, B., Alessi, J. V., Richards, A. L., Tischfield, S. E., Williams, J. N., Lamberti, G., Pecci, F., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.01.016 · Cited by 30
Self-citationAlsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 30
“STK11 mutations have been linked to PD-L1 negativity and resistance to PD-1/PD-L1 blockade [72].”
Song, P., Yang, D., Wang, H., Cui, X., Si, X., Zhang, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13447 · Cited by 23
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 25
“Besides, Serine/Threonine kinase 11 (STK11) mutation is the main driving factor of primary resistance of PD-1 inhibitors in lung adenocarcinoma (LUAC) with KRAS mutations (Skoulidis et al., 2018).”
BackgroundUpdates in the molecular pathology of non-small cell lung cancer
Paver, E. C., O'Toole, S. A., Cheng, X. M., Mahar, A. M., & Cooper, W. A. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.04.001 · Cited by 25
G�rard, M., Chatelain, C., Delaunay, T., Tostivint, E. P., Bennouna, J., & Fonteneau, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695770 · Cited by 25
Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., Lund‐Iversen, M., Brustugun, O. T., Førde, D., Paulsen, E., et al. (2021) · Cancers · doi:10.3390/cancers13174294 · Cited by 26
Mazzaschi, G., Leonetti, A., Minari, R., Gnetti, L., Quaini, F., Tiseo, M., & Facchinetti, F. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00891-8 · Cited by 25
Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer
Lee, H., Cai, F., Kelekar, N., Velupally, N., & Kim, J. (2022) · Cells · doi:10.3390/cells11010176 · Cited by 23
“…aggressive malignancy that frequently develops brain metastases [6,7], there are currently no therapies available to cure KRAS/LKB1 (KL) co-mutant NSCLC. Importantly, LKB1 loss drives primary resistance to PD-1 blockade in KRAS -driven NSCLC, rendering these tumors unfavorable to immunotherapy [8].”
BackgroundWang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
Self-citationTargeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“KRAS-STK11/LKB1 co-mutant tumors are associated with a lower response to ICPIs, a poor immune micro-environment, and low PD-L1 expression [57, 172].”
Puyalto, A., Rodríguez‐Remírez, M., López, I., Macaya, I., Guruceaga, E., Olmedo, M., Vilalta, A., Welch, C., Sandiego, S., Vicent, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01991-3 · Cited by 22
“However, only a small subset of KRAS -mutant lung cancer patients obtains a significant long-term benefit from these treatments [14–16].”
BackgroundLi, X., Tang, X., Su, J., Xu, G., Zhao, L., & Qi, Q. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113635 · Cited by 21
Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions
Nishio, H., Matsuda, R., Iwata, T., & Yamagami, W. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae019 · Cited by 26
Role of STING in the treatment of non-small cell lung cancer
Tang, W., Zhou, W., Ji, M., & Yang, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01586-x · Cited by 26
“The ineffectiveness of ICB therapy in treating KRAS-LKB1 (KL) mutant lung cancer can be partly attributed to the lack of PD-L1 expression in KL-type tumors [91].”
BackgroundChen, M., Huang, Y., Jiang, S., & Ke, C. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107966 · Cited by 21
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Kang, J., Gallucci, S., Pan, J., Oakhill, J. S., & Sanij, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1449543 · Cited by 24
“LKB1 mutation status is associated with intrinsic resistance to immunotherapy checkpoint blockade (ICB) in KRAS -mutant non-small cell lung cancer (NSCLC) (Koyama et al., 2016; Skoulidis et al., 2018).”
Immunotherapy in lung cancer brain metastases
Paisana, E., Cascão, R., Alvoeiro, M., Félix, F., Martins, G., Guerreiro, C., Roque, R., Cruz, R., Pacheco, T. R., Amado, A. C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00901-0 · Cited by 30
“Skoulidis et al. reported that mutations in STK11/LKB1 , a serine-threonine kinase, are key drivers of resistance to PD-1 axis inhibitors 72 .”
Mascaux, C., Sen, T., Sánchez‐Céspedes, M., Ortiz‐Cuaran, S., Bossé, Y., Dammeijer, F. F., Cavic, M. R., Barr, M. P., Arulananda, S., Armisén, R., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.024 · Cited by 23
Self-citationChen, H., Liu, M., Dai, Z., Li, S., Luo, Y., Wang, Y., Su, W., Cai, W., Yang, D., Huang, J., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-679 · Cited by 19
“STK11 mutation presented in our study in only one patient, which has been reported as a mediator of the cold tumor immune microenvironment and a major driver in primary resistance to PD-1 axis inhibitors in nonsquamous lung adenocarcinoma (24).”
BackgroundPromising predictors of checkpoint inhibitor response in NSCLC
Friedlaender, A., & Alfredo, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1816173 · Cited by 21
Li, Y., Xi, S., Yong, J., Wu, X., Yang, X., & Wang, F. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001744 · Cited by 22
Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma
Zhao, Z., He, B., Cai, Q., Zhang, P., Peng, X., Zhang, Y., Xie, H., & Wang, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107807 · Cited by 23
Zhang, G., Dong, R., Kong, D., Liu, B., Zha, Y., & Luo, M. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210708115406 · Cited by 21
Zyla, R. E., Hahn, E., & Hodgson, A. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207906 · Cited by 26
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 24
“Loss-of-function mutations in components of the interferon signaling pathway, such as JAK1/2, have been also identified as examples of primary resistance to ICI in melanoma [89], including upregulation of PD-L1 [95,96], loss of PTEN [97,98], lossof-function mutations of STK11/LKB1 [99,100], activation of c-Myc [101],…”
BackgroundKRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 25
Liao, X., Xia, X., Su, W. C., Yan, H., Ma, Y., Xu, L., Luo, H., Liu, W., Yin, D., Zhang, W., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.036 · Cited by 20
Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer
Sun, Q., Wei, X., Wang, Z., Zhu, Y. Y., Zhao, W., & Dong, Y. (2022) · Cancers · doi:10.3390/cancers14143294 · Cited by 24
“In addition, in KRAS-mutant lung adenocarcinoma, STK11/LKB1 inactivation induced immunosuppressive TME and innate resistance to PD-1 inhibitors through downregulation of PD-L1 in tumor cells and effector T-cell exclusion [44].”
BackgroundResultWu, F., Jiang, T., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12383 · Cited by 26
“Besides that, CD8+ tumor-infiltrating lymphocytes (TILs) [11, 12], interferon-gamma (IFN-γ) gene signature [13], tertiary lymphoid structures [14, 15] and specific genetic aberrations [16, 17] also showed potential in predicting the efficacy of ICI monotherapy in various solid tumors.”
BackgroundPeng, J., Zhang, J., Zou, D., Xiao, L., Ma, H., Zhang, X., Li, Y., Han, L., & Xie, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960459 · Cited by 27
“Patients with KL (co-mutations of KRAS and STK11) showed poor responses (13, 14).”
BackgroundSelf-citationWang, M., Zhu, L., Yang, X., Li, J., Liu, Y., & Ying, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1132158 · Cited by 27
“STK11/LKB1 mutations were linked to resistance of PD-1 blockade in KRAS-mutant lung cancer (Skoulidis et al., 2018).”
BackgroundNdembe, G., Intini, I., Moro, M., Grasselli, C., Panfili, A., Panini, N., Bleve, A., Occhipinti, M. A., Borzi, C., Garassino, M. C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02933-5 · Cited by 25
“The co-occurrence of these mutations is associated with poor prognosis, related to a particularly aggressive cancer phenotype resistant to chemo-immunotherapy, for which no targeted therapies are available [15–17].”
BackgroundDaemen, A., Cooper, J. E., Myrta, S., Wongchenko, M. J., Lin, E., Long, J. E., Foreman, O., Modrusan, Z. D., Tremayne, J. R., de la Cruz, C. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1835 · Cited by 24
“We focused our attention on STK11 status, given that STK11 mutations have been reported to drive primary resistance to anti PD-1/PD-L1 treatment (29).”
BackgroundZhang, X., Zhang, R., Chen, H., Wang, L., Ren, C., Pataer, A., Wu, S., Meng, Q. H., Ha, M. J., Morris, J. S., et al. (2020) · PubMed · Cited by 23
Self-citationEfficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
Davis, A. P., Cooper, W. A., Boyer, M. J., Lee, J., Pavlakis, N., & Kao, S. (2021) · Immunotherapy · doi:10.2217/imt-2021-0090 · Cited by 21
Self-citationKim, H., Kwon, H. J., Kim, E. S., Kwon, S., Suh, K. J., Kim, S. H., Kim, Y. J., Lee, J. S., & Chung, J.-H. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.583 · Cited by 22
“Recently, a STK11 / LKB1 co-mutation correlated with significantly shorter PFS after ICI treat-ment compared with KRAS alteration alone or KRAS / TP53 co-alteration [28].”
Self-citationPredictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Ushio, R., Murakami, S., & Saito, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071855 · Cited by 23
“A retrospective study of 174 KRASmutated NSCLC patients, including 31% with STK11/LKB1 co-mutation, demonstrated significantly lower ORR and PFS following PD-1 inhibitor therapy in STK11/LKB1-comutated patients compared with STK11/LKB1-wild-type patients [140].”
ResultThe genomic landscape of lung cancer in never-smokers from the Women’s Health Initiative
Moorthi, S., Paguirigan, A. L., Itagi, P., Ko, M., Pettinger, M. B., Hoge, A. C. H., Nag, A., Patel, N. A., Wu, F., Sather, C. L., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174643 · Cited by 24
“These genes included STK11 , also known as LKB1 , which is known to have increased prevalence in smokers (42) and confer a worse prognosis for tumors treated with PD-1/PD-L1 checkpoint inhibitors (43).”
Bragadin, A. B., Bianco, P. D., Zulato, E., Attili, I., Pavan, A., Carlet, J., Marra, L., Guarneri, V., Indraccolo, S., & Bonanno, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00704-9 · Cited by 25
Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 29
“Resistance commonly re fl ects coupled tumor cell – intrinsic alterations and extrinsic constraints in the TME, where malignant, immune, and stromal compartments continuously interact and co-evolve (32, 33).”
InfluentialLi, Y., Chen, Z., Wu, L., & Tao, W. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.163 · Cited by 20
“Driver mutations such as those in EGFR and other mutations including those in STK11, as mentioned above, are not favorable or even predict a poor response to ICIs (15,22).”
BackgroundDependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation
Zhou, X., Li, J. W., Chen, Z., Wei Min, N. I., Li, X., Yang, R., Shen, H., Liu, J., DeMayo, F. J., Lu, J., et al. (2021) · eLife · doi:10.7554/elife.66095 · Cited by 20
“…with immunosuppressive tumor microenvironment and the resistance to immune checkpoint blockade in preclinical models and clinical trials ( Skoulidis et al., 2018 ; Koyama et al., 2016 ; Kitajima et al., 2019 ), future research examining the effect of CRTC inhibition in lung cancer…”
Zhou, Y., Zhang, Y., Li, Y., Liu, L., Li, Z., Liu, Y., & Xiao, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10857 · Cited by 19
RetractedYang, Y., Shen, S., Sun, Y., Husain, H., Zhou, H., Lü, S., & Li, Z. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-88 · Cited by 21
Peng, J., Xiao, L., Zou, D., & Han, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.808378 · Cited by 22
Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer
Mata, D. A., Harries, L., Williams, E. A., Hiemenz, M., Decker, B. J., Tse, J. Y., Janovitz, T., Ferguson, D. C., Speece, I., Margolis, M. L., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0313-oa · Cited by 19
Self-citationEfficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
Peng, L., Guo, J., Kong, L., Huang, Y., Tang, N., Zhang, J., Wang, M., He, X., Li, Z., Peng, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070761 · Cited by 27
Self-citationMi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Li, C., Wang, Z., Yao, L., Lin, X., Jian, Y., Li, Y., Zhang, J., Shao, J., Tran, P. D., Hagman, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46422-5 · Cited by 24
“STK11/LKB1 alterations are the prevalent genomic driver for primary resistance to PD-1 inhibitors in KRAS -mutant lung adenocarcinoma 14 .”
Self-citationResearch progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 21
Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 22
Ruppert, A.-M., Beau‐Faller, M., Debieuvre, D., Ouafik, L., Westeel, V., Rouquette, I., Mazières, J., Bringuier, P., Monnet, I., Escande, F., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100052 · Cited by 22
“19 KRAS mutations and STK11 inactivation led to a more aggressive tumor phenotype and ICI resistance, whereas KRAS/TP53 or KRAS/ CDKN2a/B were ICI-sensitive.”
BackgroundYang, Y., Yang, J., Liang, Y., Liao, B., Zhu, W., Mo, X., & Huang, K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.642981 · Cited by 22
Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments
Yoshimura, M., Seki, K., Bychkov, A., & Fukuoka, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671799 · Cited by 22
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf153 · Cited by 27
“8,9 A particularly challenging subset of KRAS -mutant NSCLC arises when co-mutations occur in STK11 and KEAP1 , resulting in unique metabolic characteristics and treatment complexities.”
Rocca, A., Crinò, L., Braga, L., Salton, F., Ruaro, B., Confalonieri, M., Generali, D., & Confalonieri, P. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03139-6 · Cited by 30
LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence
Mitchell, K. G., Parra, E. R., Zhang, J., Nelson, D. B., Corsini, E. M., Villalobos, P. A., Moran, C. A., Skoulidis, F., Wistuba, I. I., Fujimoto, J., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.03.114 · Cited by 18
“Importantly, these mutations have been further shown to mediate resistance to inhibitors of the PD-1/PD-L1 axis (13).”
BackgroundSelf-citationXu, S., Shi, C., Xia, R., Wang, L., Tian, Z., Ye, W., Liu, L., Liu, S., Zhang, C.-Y., Hu, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798424 · Cited by 18
“Mutation in the tumor suppressor gene STK11, which regulates cell proliferation, was shown to be a negative immunotherapy predictor in non-small cell lung carcinoma (NSCLC) patients, and STK11 mutations were associated with worse survival than those without mutations (22).”
BackgroundWang, D., Chen, X., Du, Y., Li, X., Ying, L., Lü, Y., Shen, B., Gao, X., Yi, X., Xia, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.799988 · Cited by 22
“We examined whether HER2 mutation impacts treatment outcomes of ICIs in solid tumors via its association with anticancer immunity.”
BackgroundInfluentialTang, B., Hu, L., Jiang, T., Li, Y., Xu, H., Zhou, H., Lan, M., Xu, K., Yin, J., Su, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012143 · Cited by 18
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Posner, A., Sivakumaran, T., Pattison, A., Etemadmoghadam, D., Thio, N., Wood, C. S., Fisher, K., Webb, S., DeFazio, A., Wilcken, N., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005809 · Cited by 22
“Kaplan-Meier estimates of OS were presented along with log-rank tests for comparison between ICI treated CUPs, other systemic therapy treated CUPs and no systemic treatment groups.”
MethodNew Actions on Actionable Mutations in Lung Cancers
Le, X., Elamin, Y. Y., & Zhang, J. J. (2023) · Cancers · doi:10.3390/cancers15112917 · Cited by 19
“In addition, it is known that mutations in cancer genes such as STK-11 or KEAP1 are associated with ICB benefit independent of PD-L1 and tumor mutation burden [13,14], highlighting the critical potential of these genomic features as predictive biomarkers for ICB treatment.”
BackgroundSelf-citationCoschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.